About the Event
Psilocybin has shown great promise in treating many forms of mental illness including depression, alcohol addiction, anxiety and OCD.
PsyBio Therapeutics [TSXV:PSYB, OTCQB:PSYBF] is revolutionizing the development and production of psilocybin. They have over 100 molecules, 20 patents, and a process that’s far more efficient than current chemical synthesis. PsyBio can produce 12,000 doses of psilocybin in just 2.5 days.
Join our webinar to hear from PsyBio CEO, Evan Levine, as he discusses the company’s clinical path and the move toward legalization for a treatment that has the potential to help millions of people worldwide.